Lilly Cymbalta Clears FDA For Diabetes-Related Neuropathic Pain After Priority Review

Sales reps will start promoting the neuropathic pain indication to neurologists and pain specialists in the fourth quarter. After Lilly is confident duloxetine has been appropriately positioned as an antidepressant, a more active marketing of the neuropathic pain indication to primary care physicians will begin.